RU2007101705A - Индолы, полезные для лечения воспаления - Google Patents
Индолы, полезные для лечения воспаления Download PDFInfo
- Publication number
- RU2007101705A RU2007101705A RU2007101705/04A RU2007101705A RU2007101705A RU 2007101705 A RU2007101705 A RU 2007101705A RU 2007101705/04 A RU2007101705/04 A RU 2007101705/04A RU 2007101705 A RU2007101705 A RU 2007101705A RU 2007101705 A RU2007101705 A RU 2007101705A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- necessary
- group
- compound according
- halo
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title claims abstract 7
- 230000004054 inflammatory process Effects 0.000 title claims abstract 7
- 150000001875 compounds Chemical class 0.000 claims abstract 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 201000010099 disease Diseases 0.000 claims abstract 8
- 101710096361 Prostaglandin E synthase Proteins 0.000 claims abstract 5
- 230000000694 effects Effects 0.000 claims abstract 5
- 230000005764 inhibitory process Effects 0.000 claims abstract 5
- 102100033076 Prostaglandin E synthase Human genes 0.000 claims abstract 3
- 125000001424 substituent group Chemical group 0.000 claims 44
- 125000005843 halogen group Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- -1 methylenedioxy, difluoromethylenedioxy Chemical group 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical class 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 238000000926 separation method Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 claims 1
- MJPPGVVIDGQOQT-UHFFFAOYSA-N 2-bromo-5-(2-bromo-2-nitroethenyl)furan Chemical compound [O-][N+](=O)C(Br)=CC1=CC=C(Br)O1 MJPPGVVIDGQOQT-UHFFFAOYSA-N 0.000 claims 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 108091006088 activator proteins Proteins 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 229910000679 solder Inorganic materials 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58040104P | 2004-06-18 | 2004-06-18 | |
| US60/580,401 | 2004-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007101705A true RU2007101705A (ru) | 2008-07-27 |
Family
ID=34956079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007101705/04A RU2007101705A (ru) | 2004-06-18 | 2005-06-17 | Индолы, полезные для лечения воспаления |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7705023B2 (enExample) |
| EP (1) | EP1778632B1 (enExample) |
| JP (1) | JP2008502669A (enExample) |
| KR (1) | KR20070028553A (enExample) |
| CN (1) | CN101006053A (enExample) |
| AT (1) | ATE405549T1 (enExample) |
| AU (1) | AU2005254782A1 (enExample) |
| BR (1) | BRPI0512252A (enExample) |
| CA (1) | CA2570363A1 (enExample) |
| DE (1) | DE602005009209D1 (enExample) |
| ES (1) | ES2315877T3 (enExample) |
| IL (1) | IL179728A0 (enExample) |
| MX (1) | MXPA06014535A (enExample) |
| RU (1) | RU2007101705A (enExample) |
| WO (1) | WO2005123673A1 (enExample) |
| ZA (1) | ZA200610357B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1765775B1 (en) * | 2004-06-18 | 2009-04-29 | Biolipox AB | Indoles useful in the treatment of inflammation |
| BRPI0512252A (pt) | 2004-06-18 | 2008-02-19 | Biolipox Ab | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto |
| WO2006077366A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| WO2006077367A1 (en) * | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflamation |
| AR056690A1 (es) * | 2005-10-14 | 2007-10-17 | Athersys Inc | Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc |
| UA95788C2 (en) * | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
| CA2652385A1 (en) | 2006-06-08 | 2007-12-21 | Eli Lilly And Company | Novel mch receptor antagonists |
| WO2008009924A2 (en) * | 2006-07-18 | 2008-01-24 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| MX2009011210A (es) * | 2007-04-16 | 2009-10-30 | Abbott Lab | Inhibidores de mcl1 de indol 7-no sustituido. |
| CA2739901A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators |
| CN102186845B (zh) | 2008-10-17 | 2016-09-07 | 阿卡制药有限公司 | S1p受体调节剂以及它们的用途 |
| WO2010076566A2 (en) | 2008-12-30 | 2010-07-08 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| WO2010127152A2 (en) * | 2009-04-29 | 2010-11-04 | Irm Llc | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ａｍｐｋを活性化させるインダゾール化合物 |
| CN108929203A (zh) * | 2018-08-14 | 2018-12-04 | 重庆市化工研究院 | 一种芳香族乙烯基醚及其合成方法和应用 |
| CN114302874B (zh) * | 2019-08-26 | 2025-02-25 | 国际药品株式会社 | 吲哚甲酰胺衍生物和包含吲哚甲酰胺衍生物的药物组合物 |
| CN113233980B (zh) * | 2021-04-02 | 2022-04-05 | 台州学院 | 一种β-氯代酸酯及α，β-不饱和酸酯类化合物的合成方法 |
| CN118121595B (zh) * | 2024-05-06 | 2024-08-16 | 广州市朝利良生物科技有限公司 | 化合物eh-p005j在制备促伤口愈合药物中的用途 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU85435A1 (fr) | 1984-06-27 | 1986-01-24 | Amylum Graanderivaten Raff | Procede de preparation d'un carboxymethylamidon,carboxymethylamidon ainsi obtenu et produit de lavage contenant un tel carboxymethylamidon |
| US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| IL84796A (en) | 1986-12-17 | 1992-03-29 | Merck Frosst Canada Inc | Substituted n-benzyl-indoles and pharmaceutical compositions containing them |
| US5081138A (en) | 1986-12-17 | 1992-01-14 | Merck Frosst Canada, Inc. | 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith |
| US4960786A (en) | 1989-04-24 | 1990-10-02 | Merrell Dow Pharmaceuticals Inc. | Excitatory amino acid antagonists |
| PT95899A (pt) | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
| US5081145A (en) | 1990-02-01 | 1992-01-14 | Merck Frosst Canada, Inc. | Indole-2-alkanoic acids compositions of and anti allergic use thereof |
| US5374615A (en) | 1990-10-31 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives |
| PH31175A (en) | 1990-10-31 | 1998-03-20 | Squibb & Sons Inc | Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives. |
| AU641052B2 (en) | 1990-11-02 | 1993-09-09 | Aventisub Ii Inc. | 3-amidoindolyl derivatives |
| US5189054A (en) | 1990-11-02 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | 3-amidoindolyl derivatives and pharmaceutical compositions thereof |
| US5389650A (en) | 1991-09-30 | 1995-02-14 | Merck Frosst Canada, Inc. | (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
| CA2079374C (en) | 1991-09-30 | 2003-08-05 | Merck Frosst Canada Incorporated | (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
| US5234923A (en) | 1991-12-16 | 1993-08-10 | E. R. Squibb & Sons, Inc. | Substitute indole and benzimidazole derivatives |
| PT633886E (pt) | 1992-04-03 | 2001-03-30 | Upjohn Co | Aminas biciclicas-heterociclicas farmaceuticamente activas |
| US5294722A (en) | 1992-04-16 | 1994-03-15 | E. R. Squibb & Sons, Inc. | Process for the preparation of imidazoles useful in angiotensin II antagonism |
| US5236916A (en) | 1992-05-26 | 1993-08-17 | E. R. Squibb & Sons, Inc. | Oxadiazinone substituted indole and benzimidazole derivatives |
| TW229140B (enExample) | 1992-06-05 | 1994-09-01 | Shell Internat Res Schappej B V | |
| US5334719A (en) | 1992-06-17 | 1994-08-02 | Merck Frosst Canada, Inc. | Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis |
| ZA939516B (en) | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
| EP0639573A1 (de) | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
| US6075037A (en) | 1994-06-09 | 2000-06-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| MX9700696A (es) | 1994-07-27 | 1997-04-30 | Sankyo Co | Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos. |
| EP0800389A4 (en) | 1994-12-13 | 1998-04-29 | Smithkline Beecham Corp | NEW COMPOUNDS |
| US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
| JP2000516958A (ja) | 1996-08-26 | 2000-12-19 | ジェネティックス・インスチチュート・インコーポレーテッド | ホスホリパーゼ酵素の阻害剤 |
| US5910622A (en) | 1996-10-29 | 1999-06-08 | Dcv, Inc. | Method for treating fibrous cellulosic materials |
| AP9801302A0 (en) | 1997-07-23 | 2000-01-23 | Pfizer | Indole compounds as anti-inflammatory/analgesic agents.. |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| DE19742263A1 (de) | 1997-09-25 | 1999-04-01 | Asta Medica Ag | Neue spezifische Immunophilin-Liganden als Antiasthmatika, Antiallergika, Antirheumatika, Immunsuppressiva, Antipsoriatika, Neuroprotektiva |
| BR9814340B1 (pt) | 1997-12-24 | 2010-07-13 | compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica. | |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| GEP20032920B (en) | 1998-02-25 | 2003-03-25 | Genetics Inst | Inhibitors of Phospholipase Enzymes |
| US6828344B1 (en) | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| ID27280A (id) | 1998-02-25 | 2001-03-22 | Genetics Inst | Inhibitor-inhibitor dari enzim-enzim fosfolipase |
| US6916841B2 (en) | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| EE200000522A (et) | 1998-02-25 | 2002-02-15 | Genetics Institute, Inc. | Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks |
| EP1073892B1 (en) | 1998-02-27 | 2010-11-24 | Ventana Medical Systems, Inc. | Automated molecular pathology apparatus having independent slide heaters |
| US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| BR0012135A (pt) | 1999-06-29 | 2002-07-02 | Uab Research Foundation | Métodos de tratamento de infecções de fungos com inibidores de enzima sintetase nad |
| JP2001069477A (ja) * | 1999-08-31 | 2001-03-16 | Sony Corp | 番組提供システム及び番組提供方法 |
| CA2386750A1 (en) | 1999-10-22 | 2001-05-03 | Merck & Co. Inc. | Pharmaceuticals for treating obesity |
| AU7962200A (en) | 1999-10-29 | 2001-05-14 | Wakunaga Pharmaceutical Co., Ltd | Novel indole derivatives and drugs containing the same as the active ingredient |
| US6353007B1 (en) | 2000-07-13 | 2002-03-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents |
| IL154981A0 (en) | 2000-10-10 | 2003-10-31 | Smithkline Beecham Corp | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents |
| DE60203529T2 (de) | 2001-09-27 | 2006-03-16 | F. Hoffmann-La Roche Ag | Indolderivate als cox-ii-inhibitoren |
| EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| US7148250B2 (en) | 2001-12-28 | 2006-12-12 | Guilford Pharmaceuticals Inc. | Indoles as NAALADase inhibitors |
| AU2003272285A1 (en) | 2002-09-06 | 2004-03-29 | Janssen Pharmaceutica, N.V. | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands |
| JP2007516203A (ja) | 2003-07-09 | 2007-06-21 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
| MXPA06014536A (es) | 2004-06-18 | 2007-06-05 | Biolipox Ab | Indoles utiles en el tratamiento de inflamacion. |
| BRPI0512252A (pt) | 2004-06-18 | 2008-02-19 | Biolipox Ab | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto |
| WO2006077364A1 (en) * | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| US20090088472A1 (en) | 2005-05-17 | 2009-04-02 | Kouji Oohashi | Protective Agent for Neuronal Cell Comprising Amidino Derivative as Active Ingredient |
-
2005
- 2005-06-17 BR BRPI0512252-0A patent/BRPI0512252A/pt not_active IP Right Cessation
- 2005-06-17 WO PCT/GB2005/002391 patent/WO2005123673A1/en not_active Ceased
- 2005-06-17 JP JP2007516043A patent/JP2008502669A/ja not_active Withdrawn
- 2005-06-17 MX MXPA06014535A patent/MXPA06014535A/es unknown
- 2005-06-17 ES ES05751812T patent/ES2315877T3/es not_active Expired - Lifetime
- 2005-06-17 EP EP05751812A patent/EP1778632B1/en not_active Expired - Lifetime
- 2005-06-17 CN CNA2005800277808A patent/CN101006053A/zh active Pending
- 2005-06-17 KR KR1020077001307A patent/KR20070028553A/ko not_active Withdrawn
- 2005-06-17 AU AU2005254782A patent/AU2005254782A1/en not_active Abandoned
- 2005-06-17 DE DE602005009209T patent/DE602005009209D1/de not_active Expired - Lifetime
- 2005-06-17 ZA ZA200610357A patent/ZA200610357B/en unknown
- 2005-06-17 RU RU2007101705/04A patent/RU2007101705A/ru not_active Application Discontinuation
- 2005-06-17 CA CA002570363A patent/CA2570363A1/en not_active Abandoned
- 2005-06-17 US US11/629,624 patent/US7705023B2/en not_active Expired - Fee Related
- 2005-06-17 AT AT05751812T patent/ATE405549T1/de not_active IP Right Cessation
-
2006
- 2006-11-30 IL IL179728A patent/IL179728A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200610357B (en) | 2008-02-27 |
| JP2008502669A (ja) | 2008-01-31 |
| DE602005009209D1 (de) | 2008-10-02 |
| MXPA06014535A (es) | 2007-06-05 |
| BRPI0512252A (pt) | 2008-02-19 |
| EP1778632A1 (en) | 2007-05-02 |
| US20070287715A1 (en) | 2007-12-13 |
| AU2005254782A1 (en) | 2005-12-29 |
| WO2005123673A1 (en) | 2005-12-29 |
| CA2570363A1 (en) | 2005-12-29 |
| US7705023B2 (en) | 2010-04-27 |
| ATE405549T1 (de) | 2008-09-15 |
| IL179728A0 (en) | 2007-05-15 |
| CN101006053A (zh) | 2007-07-25 |
| EP1778632B1 (en) | 2008-08-20 |
| ES2315877T3 (es) | 2009-04-01 |
| KR20070028553A (ko) | 2007-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007101703A (ru) | Индолы, полезные при лечении воспаления | |
| WO1992009279A1 (fr) | Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive | |
| JPH01110675A (ja) | ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤 | |
| JP2008502670A5 (enExample) | ||
| JPS62103065A (ja) | ピリジン誘導体 | |
| JPS59501409A (ja) | ピリドン化合物 | |
| JP2008502669A5 (enExample) | ||
| JPS5822119B2 (ja) | ジチオ−ル誘導体 | |
| JPWO1998046594A1 (ja) | ピラゾール誘導体およびそれを含有するｃｏｘ阻害剤 | |
| JPS6277375A (ja) | Ｎ―置換２―アミノチアゾール類及び治療用組成物 | |
| EP4286001A2 (en) | Benzoylglycine derivatives and methods of making and using same | |
| JPS62252780A (ja) | 新規なインデノチアゾ−ル誘導体及びその製造法 | |
| KR20080067364A (ko) | 리폭시게나제 억제제로서의 트리아졸 화합물 | |
| JP2009511559A5 (enExample) | ||
| CN1056369C (zh) | 哒嗪酮衍生物或其盐和制备方法 | |
| JP2003012667A (ja) | キノリンカルボキサミド骨格を有する抗菌剤 | |
| JPH06505728A (ja) | 長鎖の抗ウィルス化合物 | |
| JP2008502672A5 (enExample) | ||
| CN102603585B (zh) | N-苯基-2-巯基苯甲酰胺衍生物及其制备方法和用途 | |
| JP3042915B2 (ja) | ３−（１ｈ−インダゾール−３−イル）−４−ピリジンアミンおよびその製造法 | |
| JPH05502235A (ja) | イミダゾール類 | |
| JPH01199979A (ja) | 新規キノリンカルボン酸誘導体および該化合物を有効成分とする抗菌剤 | |
| JP2786683B2 (ja) | グリコール誘導体およびその用途 | |
| JP2008520611A5 (enExample) | ||
| JPS62240678A (ja) | 複素環で置換されたベンズイミダゾ−ル、その製法及びこれを含有する心臓−及び循環疾病の治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090901 |